

Part A. PERSONAL INFORMATION

CV date

07/07/2023

First name	FRANCISCO JAVIER		
Family name	CUBERO PALERO		
Gender	Male		
Social Security, Passport, ID	50857577T	Birth date	09/12/1974
E-mail	fcubero@ucm.es		
Researcher codes	Open Researcher and Contributor ID (ORCID**)	0000-0003-1499-650X	
	SCOPUS Author ID (*)	8517959700	
	WoS Researcher ID (*)	G-8564-2018	

A.1. Current position

Position	Catedrático de Universidad (Full Professor)		
Initial Date	21/02/2022		
Institution	Universidad Complutense de Madrid (UCM)		
Department	Departamento de Inmunología, Oftalmología y Otorrinolaringología		
Country	SPAIN	Tel. number	(+34) 913941385; 671251556
Keywords	Liver, ER, JNK, ALD, DILI, Cholestasis, HCC/CCA		

A.2. Previous positions

Period	Position/Institution/Country/Interruption cause
2016-2022	Ramón y Cajal Researcher/PDI, Facultad Medicina (UCM), Madrid, Spain
2009-2016	Senior Scientist/Principal Investigator (UKA Aachen, Germany)
2006-2009	Postdoctoral Researcher (Becario MEC Postdoc), Mount Sinai (NY, USA)
2004-2006	Teaching Assistant and Lecturer (Trinity College Dublin, Ireland)
2001-2004	Becario Predoctoral FISS (Cirugía Exp., Hosp. Puerta Hierro, Madrid, Spain)
1998-2000	Becario Técnico CAM, Facultad Biología (UCM), Madrid, Spain

A.3. Education

Bachelor/Master/PhD	University	Year
Bachelor in Science (B.Sc.)	Universidad Complutense de Madrid	1997
Master in Science (M.Sc.)	Universidad Complutense de Madrid	2000
Doctor in Biology (Physiology) (Ph.D.)	Universidad Complutense de Madrid	2004

Part B. CV SUMMARY

I graduated in the Universidad Complutense Madrid (UCM) and started my predoctoral stage as a student-collaborator in Dr. Rosa Maria Arahuetes's lab, granted with a Fellowship from the Regional Government of Madrid. During this period, I began a profitable collaboration with Dr. Paloma Maganto, at the Service of Experimental Surgery in Puerta de Hierro Hospital. I focused his MSc thesis on the expression of bilirubin UDP-glucuronosyl transferase throughout fetal development. With the financial support of a predoctoral fellowship of the Spanish FISS (ISCIII), I then studied hepatocyte transplantation as an alternative to orthotopic liver transplant in liver-based inborn errors of metabolism, such as the Crigler-Najjar syndrome type I. The doctoral thesis, outstanding *cum laude*, was titled "Intrasplenic transplantation of hepatocytes in an experimental model of type I Crigler-Najjar syndrome". My postdoctoral experience began at Trinity College Dublin in Anatomy and Physiology under the Supervision of Prof. Gabrielle McKee (2004-2006). Later, I joined Dr. Natalia Nieto's lab, in the Division of Liver Diseases at Mount Sinai School of Medicine as a postdoctoral fellow first and then as a recipient of a postdoctoral fellowship from the Spanish Ministry of

Science and Education (Beca MEC/Fulbright), under the auspices of Prof. Scott Friedman. Using his expertise in primary hepatocyte isolation (both fetal and adult), experimentally approached the study of the pathophysiology of alcohol-induced liver fibrosis (2006-2009). In 2009, I joined the research group headed by Prof. Trautwein (University Hospital RWTH Aachen) who is an international expert on the functional relevance of cell- type specific signaling pathways in animal models of liver injury and where I became Research Associate (2009-2016).

In 2016, I obtained a Ramon y Cajal Fellowship and in February 2022, I was appointed Catedrático de Inmunología (Full Professor) in the Department of Immunology, Ophthalmology and ENT at the Complutense University School of Medicine.

I participate in national (ISCIII/MICINN/ANEP) and international evaluation procedures (ANR-France, DFG-Germany, MRC-UK, Czech Science Foundation). I belong to the Editorial Board of Gut, Journal of Hepatology, World Journal of Gastroenterology, Livers, European Journal of Anatomy and Explorative Digestive Diseases and I am a member of the COST Action CA18122 EURO-CHOLANGIO-NET (2019-2023), Cost Action CA11712 ProEURO DILI Registry (2018-2022) in which I am the Short Term Scientific Missions (STSM) Coordinator, Core Group member and Grant Awarding Coordinator. Since January 2023 I am member of the Scientific Committee of the Spanish Association for the Study of the Liver (AEEH) and I am the Coordinator of the HORIZON-HLTH-2022-STAYHLTH-02 financed with 6,348,927.28 € "Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (nonalcoholic steatohepatitis) transition to inform early prevention and treatment strategies", part of the Steering Committee of EASL DHILI Consortium and Scientific Committee member of Spanish Association for the Study of the Liver (AEEH). Moreover, I am a member the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Disease (AASLD) and the International Society for Hepatic Sinusoidal Research (ISHSR).

During my career, I have received relevant Honors and Awards including the ERAB Best Publication Award (2020), International Liver Scholar Award, Gilead (2018-2020), German Liver Foundation Award (2016), Ramon y Cajal Fellowship (2016-2022), Torres Quevedo Fellowship (2015, declined), Postdoctoral Fellowship of the New York Center for Systems Biology (2008), Liver Scholar Award (2008), Postdoctoral Fellowship, MEC (2006-2018) and the Predoctoral Fellowship, Comunidad Autónoma de Madrid (1997-2000).

Parte C. RELEVANT MERITS

I have published over 100 scientific papers indexed in Pubmed including Reviews and Editorials; most of the papers published in D1 and published in journals with an impact factor (IF) higher than 10. Total Citations: 2747, Last 5 year Citations: 2186; h-Index 33 (Google Scholar).

C.1.Publications

Articles

- 1.-Ye H, Chen C, Wu H, Zheng K, Martín-Adrados B, Caparros E, Francés R, Nelson LJ, Gómez Del Moral M, Asensio I, Vaquero J, Bañares R, Ávila MA, Andrade RJ, Isabel Lucena M, Martínez-Chantar ML, Reeves HL, Masson S, Blumberg RS, Gracia- Sancho J, Nevzorova YA, Martínez-Naves E, **Cubero FJ***. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy. Cell Death Dis. 2022 Feb 10;13(2):143 (23/23). IF:8,469, Q1. *AP: Senior and corresponding author.
- 2.-Fernandez-Checa JC, Bagnaninchi P, Ye H, Sancho-Bru P, Falcon-Perez JM, Royo F, Garcia-Ruiz C, Konu O, Miranda J, Lunov O, Dejneka A, Elfick A, McDonald A, Sullivan GJ, Aithal GP, Lucena MI, Andrade RJ, Fromenty B, Kranendonk M, **Cubero FJ***, Nelson LJ*. Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO- DILI-NET]. J Hepatol. 2021 Oct;75(4):935-959 (20/21). IF: 25,083 (D1). *AP: co-Senior author.

- 3.-Chen C, Wu H, Ye H, Tortajada A, Rodríguez-Perales S, Torres-Ruiz R, Vidal A, Trautwein C, Davis RJ, Martinez-Naves E, Nevzorova YA, Villanueva A, Avila MA, **Cubero FJ***. Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. *Cancers (Basel)* 2021 Dec 24;14(1):78 (14/14). IF: 6,639 (Q1). *AP: senior author and corresponding.
- 4.-Nevzorova YA; Boyer-Diaz Z; **Cubero FJ***; Gracia-Sancho J*. Animal Models for Liver Disease-A practical approach for translational research. *Journal of Hepatology* 2020; 73(2):423-440 (3/4). IF: 20,582 (D1), * AP: Senior and co-corresponding author.
- 5.-Liao L, Schneider KM, Galvez EJC, Frissen M, Marschall HU, Su H, Hatting M, Wahlstrom A, Haybaeck J, Puchas P, Mohs A, Peng J, Bergheim I, Nier A, Hennings J, Reising J, Zimmermann HW, Longerich T, Strowig T, Liedtke C, **Cubero FJ***, Trautwein C*. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing colangitis. *Gut* 2019;68 (8):1477-1492. (21/22), IF: 17,943 (D1), *AP: Senior and co-corresponding author.
- 6.-**Cubero FJ***, Peng J, Liao L, Su H, Zhao G, Eugenio Zoubek M, Macías-Rodríguez R, Ruiz-Margain A, Reißing J, Zimmermann HW, Gassler N, Luedde T, Liedtke C, Hatting M, Trautwein C. Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis. *J Hepatol.* 2018; 69(6):1326-1334. (1/15), IF: 18.946 (D1). AP: first authorship.
- 7.-Mohs A, Kuttkat N, Reißing J, Zimmermann HW, Sonntag R, Proudfoot A, Youssef SA, de Bruin A, **Cubero FJ***; Trautwein C. Functional role of CCL5/RANTES for HCC progression during chronic liver disease. *Journal of Hepatology* 2018; 66(2):743-753. (9/10), IF: 18,946 (D1), *AP: Senior co-author.
- 8.-Kuttkat N; Mohs A; Ohl K; Hooiveld G; Longerich T; Tenbrock K; **Cubero FJ***; Trautwein C. Hepatic overexpression of cAMP-responsive element modulator a induces a regulatory T-cell response in a murine model of chronic liver disease. *Gut* 66 (5): 908-919. (7/8), IF: 17,943 (D1), *AP: Senior and co-corresponding author.
- 9.-**Cubero FJ***, Zoubek ME, Hu W, Peng J, Zhao G, Nevzorova YA, Al Masaoudi M, Bechmann LP, Boekschoten MV, Muller M, Preisinger C, Gassler N, Canbay AE, Luedde T, Davis RJ, Liedtke C, Trautwein C. Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury. *Gastroenterology* 2016; 150: 968-81. (1/17), IF: 19,233 (D1), AP: first authorship.

Books

- 1.-Morán L, Woitok MM, Bartneck M, **Cubero FJ**. Hepatocyte-directed delivery of lipid-encapsulated small interfering RNA. *Methods Mol Biol.* 2022;2544:95-106 (doi: 10.1007/978-1-0716-2557-6_6).
- 2.-Lucena MI, Andrade RA, Cubero FJ. Obesidad: factor agravante de la toxicidad hepática por fármaco en Hepatología clínica y trasplante hepático. Vol I: pp 165-170. Edit. Permanyer, Barcelona, Spain: ISBN 978-84-9926-997-9 (2017).
- 3.-Nevzorova YA, **Cubero FJ**. Células esterales hepáticas: directores de orquesta de la sinfonía hepática en Hepatología clínica y trasplante hepático. Vol I: pp 13-18. Edit. Permanyer, Barcelona, Spain: ISBN 978-84-9926-997-9 (2017).
- 4.-**Cubero FJ**, Trautwein C. Molecular Pathology of Liver Diseases:Oxidative stress and liver injury, pp 427-436. Edit. Springer, New York, US. ISBN 978-1-4419-7106-7 (2011).

C2. Congresses

- ISBRA & ESBRA Congress, Cracow, Poland, 17-20 Sept 2022.
Blood and faecal extracellular vesicles (EVs) as biomarkers of injury in the gut-liver axis during alcohol-induced liver disease. **F. J. Cubero**. Invited Conference.
- 3º Reunión de Hepatología Traslacional (AEEH), Alicante, España, 22-23 Oct 2021.
Estrés oxidativo y muerte celular. **F. J. Cubero**. Invited Conference.
- 1º Reunión Hepatología Traslacional, San Sebastián, España, 4-5, Oct 2019.
Anatomy and Embriology of the liver. FJ Cubero. Invited Conference.
- AMMF, The Cholangiocarcinoma Charity Annual Meeting, Stansted (UK), 8-10 May 2019.
A novel model of cholangiocarcinoma. Cubero FJ. Oral Communication

- 4th ISHR (International Symposium on Cells of the Hepatic Sinusoid, Sydney, Australia, 4-7 Sept 2019. Genetic deletion of Keap1 in hepatocytes triggers hepatitis in an Nrf2- dependant manner in an experimental toxic injury model. Cubero FJ. Conferencia Invitada

C.3. Research Projects and Funds

- *Dissecting the activation of liver-generated microglia and neuroinflammation during alcohol misuse.*
Funding Body: ERAB EA1814.
Participant entities: Universidad Complutense de Madrid y Universidad Miguel Hernández.
Duration: 2019-2021. Amount: 70.000 Euros
PI: Francisco Javier Cubero
- *A novel therapy against cholangiocarcinoma.*
Funding Body: AMMF 2018/117.
Participant entities: UCM, CIMA (Pamplona) and University of Edinburgh (UoE).
Duration: 2018-2020. Amount: 67.000 sterling pounds
PIs: Francisco Javier Cubero, Matías A. Ávila and Leonard J. Nelson.
- *Interdependence of oxidative stress and inflammation during chronic liver injury: a novel tool for theranostics.*
Funding Body: GILEAD 44/2018. Participant entities: UCM.
Duration: 2018-2020. Amount: 130.000 Euro
PI: Francisco Javier Cubero
- *Deconstructing the role of JNK and ER stress in alcoholic liver injury.* Funding body: MINECO RETOS; SAF2016-78711
Participant entities: UCM.
Duration: 2016-2019. Amount: 170.000 Euro
PI: Francisco Javier Cubero Palero and Eduardo Martínez-Naves
- *Nuevas aplicaciones de la nanotecnología en la enfermedad hepática crónica*
Funding body: Comunidad de Madrid; Y2018/NMT-4949
Participant entities: Fundación Hospital Universitario Gregorio Marañón
Duration: 2019-2022. Amount: 771.100 Euro
PI: Rafael Bañares and Manuel Descó (Francisco Javier Cubero, Team Member)
- *Comunicación por exosomas y otras vesículas extracelulares en la fisiología y fisiopatología hepática.*
Funding body: Comunidad de Madrid B2017/BMD-3727 Participant entities: Multiple regional
Duration: 2018-2021. Amount: 843.000 Euro
PI: Rafael Bañares and Eduardo Martínez-Naves (Francisco Javier Cubero, Team Member)
- *ESTRÉS DEL RETÍCULO ENDOPLÁSMICO Y SEÑALIZACIÓN DE JNK EN LA INFLAMACIÓN CRÓNICA: COMPRENDIENDO EL CAMINO A LA MALIGNIFICACIÓN EPITELIAL*
Funding Body: MICINN PID117941RB-I00
Duration: 2021-2024. Amount: 126.000 Euros
PI: Francisco Javier Cubero Palero and Eduardo Martínez Naves
- *Vesículas extracelulares en la fisiopatología hepática: Relevancia mecanística, diagnóstica y terapéutica (EXOHEP2CM).* Funding body: Comunidad de Madrid S2022/BMD-7409; Participant entities: Multiple regional Duration: 2023-2027. Amount: 756,800 Euro
PI: Francisco Javier Cubero, Rafael Bañares, Laura Moreno and Alberto Dávalos.
- *Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (nonalcoholic steatohepatitis) transition to inform early prevention and treatment strategies*
Funding body: HORIZON-HLTH-2022-STAYHLTH-02 Participant entities: 18 european
Duration: 2023-2027. Amount: 6,348,927.28 Euro
Coordinator: Francisco Javier Cubero

C.4. Contracts

- Identification of kinases responsible for cell death processes in liver disease. Funding Body: art. 83; 211/2016; RWTH Aachen University Participant entities: Universidad Complutense de Madrid
Duration: June. 2016-December, 2016. Amount: 18.000 EUR, PI: FJ Cubero.